Consensus statement of the management of severe, difficult-to-treat atopic dermatitis in adults and adolescents in South Africa and the role of biologics

Simple item page
dc.contributor.authorKannenberg, Susanna Men_ZA
dc.contributor.authorKarabus, Sarah Jen_Za
dc.contributor.authorLevin, Michaelen_ZA
dc.contributor.authorMabelane, Tshegofatsoen_ZA
dc.contributor.authorManjra, Ahmed Ien_ZA
dc.contributor.authorPillay, Lushenen_ZA
dc.contributor.authorRaboobee, Noufalen_ZA
dc.contributor.authorSingh, Rajendrakumaren_ZA
dc.contributor.authorVan Niekerk, Andréen_ZA
dc.contributor.authorWeiss, Roberten_ZA
dc.contributor.authorVisser, Willem Ien_ZA
dc.date.accessioned2023-05-02T07:17:07Zen_ZA
dc.date.available2023-05-02T07:17:07Zen_ZA
dc.date.issued2021-09en_ZA
dc.descriptionCITATION: Kannenberg, S. M. et al., (2021) Consensus statement of the management of severe, difficult-to-treat atopic dermatitis in adults and adolescents in South Africa and the role of biologics. Current Allergy and Clinical Immunology 34(3):9 pages. doi.10.10520/ejc-caci-v34-n3-a10en_ZA
dc.descriptionThe original publication is available at: journals.co.zaen_ZA
dc.description.abstractThe first biological agent for treatment of moderate-to-severe atopic dermatitis (AD), dupilumab, has recently been introduced to South Africa and guidance is required as to its place in therapy. Consequently, an expert panel was convened to reach consensus on 14 statements relevant to contemporary management of AD and the use of dupilumab. In summary, the objectives of therapy are to reduce skin inflammation and pruritus, restore skin-barrier function, avoid lfares, and improve quality of life. Useful comprehensive scoring tools to assess severity of AD and guide decisions to step up from topical to systemic therapy (including to a biologic agent), include SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI). In addition, a photographic record of pre-treatment and follow-up assessments is helpful. When systemic therapy is required, options include cyclosporin, which should be limited to short-term use, and off-label use of methotrexate. Systemic corticosteroids should be considered only in short courses for rescue therapy in the event of flares. New classes of medication for the treatment of moderateto-severe AD are in various stages of development. The two most prominent classes of new therapies are biologics and small molecules. Dupilumab is the first fully humanised monoclonal antibody (MAB) biologic approved for the treatment of moderate-to-severe AD. It is an effective and well-tolerated, long-term treatment and has a favourable safety profile.en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent9 pagesen_ZA
dc.identifier.citationKannenberg, S. M. et al., (2021) Consensus statement of the management of severe, difficult-to-treat atopic dermatitis in adults and adolescents in South Africa and the role of biologics. Current Allergy and Clinical Immunology 34(3):9 pages. doi.10.10520/ejc-caci-v34-n3-a10en_ZA
dc.identifier.issn1609-3607 (online)en_ZA
dc.identifier.otherdoi.10.10520/ejc-caci-v34-n3-a10en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126854en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherAllergy Society of South Africa (ALLSA)en_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectAtopic dermatitis -- Treatment -- South Africaen_ZA
dc.subjectBiologicals -- South Africaen_ZA
dc.subjectMonoclonal antibodies -- Therapeutic use -- South Africaen_ZA
dc.subjectDupilumaben_ZA
dc.titleConsensus statement of the management of severe, difficult-to-treat atopic dermatitis in adults and adolescents in South Africa and the role of biologicsen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
susan_consensus_2021.pdf
Size:
330.85 KB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Dermatology)